Korea Institute of Science and Technology

K2b Therapeutics, Inc.

Goldstar, Co., Ltd.

Hong Yeol Yoon

Ick Chan Kwon

Sun Hwa Kim

Kwangmeyung Kim

Jay S Kim

Ju Hee Ryu

Yoo Soo Yang

Jong Won Lee

In-San Kim

Man Kyu Shim

HoWon J Kim

Inchan Youn

Kwang Meyung Kim

Jae Hyung Park

Hyun Su Min

Juho Park

Seong G Kang

Suah Yang

Gi-Jung Kwak

Heui W Kim

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a fibrotic cell.

The present disclosure relates to a pharmaceutical composition for combination therapy for preventing or treating cancer, which contains a first pharmaceutical ingredient containing a drug conjugate wherein an anticancer agent is bound at one end of an amphiphilic peptide represented by SEQ ID NO 1 and a poloxamer; and a second pharmaceutical ingredient containing an anti-PD-L1 antibody; as active ingredients. The pharmaceutical composition significantly inhibits cancer growth in in-vivo experiments and exhibits an effect of significantly enhancing immunotherapeutic effect by activating immune cells in cancerous tissues. In particular, the pharmaceutical composition for combination therapy according to the present disclosure has superior tumor accumulation efficiency and selectivity as compared to existing anticancer agents, and is very stable with little toxicity to normal tissues other than cancerous tissues.

Pharmaceutical composition for combination therapy for preventing or treating cancer containing tumor-specific drug conjugate and anti-PD-L1 antibody as active ingredients

The present invention relates to a novel anti-miRNA single-stranded nucleic acid maleimide derivative, which comprises an anti-miRNA single-stranded nucleic acid having a nucleic acid sequence complementary to a nucleic acid sequence of an miRNA. Further, the present invention provides an anti-miRNA single-stranded nucleic acid-serum albumin conjugate in which serum albumin is covalently bonded to the anti-miRNA single-stranded nucleic acid maleimide derivative via the maleimide group.

Therapeutic agent for treating cancer comprising anti-miRNA-albumin composite

The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin B in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby providing a target for action as a contrast agent. Accordingly, because the azide is exposed to the cell surface only by cathepsin B, as it is specifically expressed in cancer cells, in particular in metastatic cancer cells, while it is limitedly expressed in normal cells and is hardly excreted out the cells, the cancer cells can be selectively imaged by an azide-specific contrast agent.

Glycopeptide for contrast agent targeting cancer cells and contrast agent kit containing the same

Disclosed is a liver tumor-targeting ultrasound contrast agent. The ultrasound contrast agent includes a gas-generating core and a hyaluronic acid shell. The ultrasound contrast agent can be specifically delivered to liver cells. This specific delivery enables easy differentiation between normal liver cells and liver tumor cells by ultrasound imaging. In addition, the ultrasound contrast agent is highly stable in aqueous condition and causes no cytotoxicity. Also disclosed is a method for preparing the ultrasound contrast agent.

Liver tumor-targeting ultrasound contrast agent and method for preparing the same

A water spraying device for a tableware washer. The water spraying device comprises a rotatable frame, a water spraying arm rotatably supported by the frame and turned along with the frame, a water guide member for guiding the water to the spraying arm. The fixed shaft is mounted on the water guide member such that it vertically penetrates the support frame and exposes its top end to bile outside of the support frame. The support member is fixedly mounted on the top end of the shaft. The guider having a guide slot is fixedly mounted on the spraying arm. The connecting rod is movably placed on the support frame and levered by a hinge pin of the support frame, thus to convert a turning motion of the support frame into an opposed directional rotating motion of the spraying arm and to change the direction of the water spraying holes of the arm. The spraying device makes the spraying arm repeat an opposed directional rotation simultaneously with turning when the upper frame is turned, thus to enlarge the water spraying range and be improve the washing efficiency of the tableware washer.

Water spraying device for tableware washer

Growing community of inventors

Seoul, South Korea

Hong Yeol Yoon